A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy

Authors GlaxoSmithKline -More
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2003
Links ClinicalTrials.gov
This is a 48-week study to evaluate the safety and efficacy of a new tablet formulation containing two FDA-approved drugs in HIV-infected patients who have not received prior therapy. This tablet will be taken with one of two FDA-approved drugs as a once-daily regimen. Study physicians will evaluate subjects to determine if they have certain medical conditions, laboratory test values, medication use, or drug allergies that would exclude them from the study.
Epistemonikos ID: 9a6fa1ff7d9c78ccacd980343bad7f7b3db8d278
First added on: Dec 01, 2021